479 related articles for article (PubMed ID: 37108625)
1. Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses.
Foglia B; Beltrà M; Sutti S; Cannito S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108625
[TBL] [Abstract][Full Text] [Related]
2. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.
Shang RZ; Qu SB; Wang DS
World J Gastroenterol; 2016 Dec; 22(45):9933-9943. PubMed ID: 28018100
[TBL] [Abstract][Full Text] [Related]
4. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
5. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma.
Wang N; Tan HY; Lu Y; Chan YT; Wang D; Guo W; Xu Y; Zhang C; Chen F; Tang G; Feng Y
Signal Transduct Target Ther; 2021 Feb; 6(1):86. PubMed ID: 33633112
[TBL] [Abstract][Full Text] [Related]
6. Identification of Proteome-Based Immune Subtypes of Early Hepatocellular Carcinoma and Analysis of Potential Metabolic Drivers.
Diao L; He M; Xu B; Chen L; Wang Z; Yang Y; Xia S; Hu S; Guo S; Li D
Mol Cell Proteomics; 2024 Jan; 23(1):100686. PubMed ID: 38008179
[TBL] [Abstract][Full Text] [Related]
7. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
10. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
Xu K; Xia P; Chen X; Ma W; Yuan Y
Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
[TBL] [Abstract][Full Text] [Related]
11. [Cancer metabolism: a novel perspective on precision diagnosis and treatment for liver cancer].
Ning Z; Tan G
Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):31-36. PubMed ID: 31902167
[TBL] [Abstract][Full Text] [Related]
12. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.
Xu FQ; Dong MM; Wang ZF; Cao LD
Front Immunol; 2023; 14():1083069. PubMed ID: 36776894
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
14. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment.
Cassim S; Raymond VA; Dehbidi-Assadzadeh L; Lapierre P; Bilodeau M
Cell Cycle; 2018; 17(7):903-916. PubMed ID: 29633904
[TBL] [Abstract][Full Text] [Related]
16. The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
Liao W; Du J; Wang Z; Feng Q; Liao M; Liu H; Yuan K; Zeng Y
Int J Cancer; 2022 Aug; 151(3):337-347. PubMed ID: 35460073
[TBL] [Abstract][Full Text] [Related]
17. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.
Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X
Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591
[TBL] [Abstract][Full Text] [Related]
18. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Zhao C; Wang B; Liu E; Zhang Z
Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
[TBL] [Abstract][Full Text] [Related]
19. Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma Development.
Serra M; Di Matteo M; Serneels J; Pal R; Cafarello ST; Lanza M; Sanchez-Martin C; Evert M; Castegna A; Calvisi DF; Mazzone M; Columbano A
Cell Mol Gastroenterol Hepatol; 2022; 14(3):609-624. PubMed ID: 35714859
[TBL] [Abstract][Full Text] [Related]
20. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.
Tian LY; Smit DJ; Jücker M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
